keyword
MENU ▼
Read by QxMD icon Read
search

lysis tumoral syndrome

keyword
https://www.readbyqxmd.com/read/27885340/acute-kidney-injury-in-hematopoietic-stem-cell-transplantation-a-review
#1
REVIEW
Vinod Krishnappa, Mohit Gupta, Gurusidda Manu, Shivani Kwatra, Osei-Tutu Owusu, Rupesh Raina
Hematopoietic stem cell transplantation (HSCT) is a highly effective treatment strategy for lymphoproliferative disorders and bone marrow failure states including aplastic anemia and thalassemia. However, its use has been limited by the increased treatment related complications, including acute kidney injury (AKI) with an incidence ranging from 20% to 73%. AKI after HSCT has been associated with an increased risk of mortality. The incidence of AKI reported in recipients of myeloablative allogeneic transplant is considerably higher in comparison to other subclasses mainly due to use of cyclosporine and development of graft-versus-host disease (GVHD) in allogeneic groups...
2016: International Journal of Nephrology
https://www.readbyqxmd.com/read/27851606/1972-spontaneous-tumor-lysis-syndrome-from-a-solitary-metastatic-cns-nonseminomatous-germ-cell-tumor
#2
Brandon Nokes, Richard Zimmerman, Naresh Patel, Matthew Zarka, Alyssa Chapital
No abstract text is available yet for this article.
December 2016: Critical Care Medicine
https://www.readbyqxmd.com/read/27816725/blinatumomab-provoked-fatal-heart-failure
#3
REVIEW
Behrad Darvishi, Leila Farahmand, Neda Jalili, Keivan Majidzadeh-A
Mentioned in Blinatumomab (Blincyto®) clinical safety report, a 5 year old boy with acute lymphoblastic leukemia (ALL) receiving Blincyto® with the concentration of 30μg/m(2)/day on the fourth day of therapy developed both Cytokine Release Syndrome (CRS) and Tumor Lysis Syndrome (TLS). Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Bilirubin peaks were 18, 7 and 8 folds more than upper normal limit (UNL) respectively. However, albumin was reduced to approximately half of the lower Normal limit (LNL)...
October 28, 2016: International Immunopharmacology
https://www.readbyqxmd.com/read/27759721/recognizing-and-preventing-tumor-lysis-syndrome
#4
(no author information available yet)
No abstract text is available yet for this article.
November 2016: Nursing
https://www.readbyqxmd.com/read/27759720/recognizing-and-preventing-tumor-lysis-syndrome
#5
Roberta Kaplow, Karen Iyere
No abstract text is available yet for this article.
November 2016: Nursing
https://www.readbyqxmd.com/read/27750483/the-cdk-inhibitor-at7519m-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-and-mantle-cell-lymphoma-a-phase-ii-study-of-the-canadian-cancer-trials-group
#6
Matthew D Seftel, John Kuruvilla, Tom Kouroukis, Versha Banerji, Graeme Fraser, Michael Crump, Rajat Kumar, Haji I Chalchal, Muhammad Salim, Rob C Laister, Susan Crocker, Spencer B Gibson, Marcia Toguchi, John F Lyons, Hao Xu, Jean Powers, Joana Sederias, Lesley Seymour, Annette E Hay
AT7519M is a small molecule inhibitor of cyclin-dependent kinases 1, 2, 4, 5, and 9 with in vitro activity against lymphoid malignancies. In two concurrent Phase II trials, we evaluated AT7519M in relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) using the recommended Phase II dosing of 27 mg/m(2) twice weekly for 2 of every 3 weeks. Primary objective was objective response rate (ORR). Nineteen patients were accrued (7 CLL, 12 MCL). Four CLL patients achieved stable disease (SD)...
October 17, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27746444/tumor-lysis-like-syndrome-in-eosinophilic-disease-of-the-lung-a-case-report-and-review-of-the-literature
#7
Seiya Urae, Kayori Tsuruoka, Sayaka Kuroya, Yugo Shibagaki
Tumor lysis syndrome (TLS) is a metabolic disorder that is generally associated with a malignancy leading to hyperuricemia, hyperphosphatemia, and acute kidney injury. On the other hand, we sometimes encounter these phenomena in nonmalignant disease, which has been referred to as tumor lysis-like syndrome in some studies. We herein experienced a case in which tumor lysis-like syndrome occurred in the course of therapy for eosinophilic disease of the lung, a nonmalignant disease. Even in nonmalignant disease, massive cell lysis induced by therapy can cause phenomena such as TLS or tumor lysis-like syndrome...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27728330/spontaneous-tumor-lysis-syndrome-in-chronic-myeloid-leukaemia-a-case-report
#8
Lincy Vinayan M, Usha Padmini, Balamurughan, Selvamani, K Sivakumar
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27728093/spontaneous-tumor-lysis-syndrome-in-chronic-myeloid-leukaemia-a-case-report
#9
Lincy Vinayan M, Usha Padmini, Balamurughan, Selvamani, K Sivakumar
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27702489/utilizing-intein-mediated-protein-cleaving-for-purification-of-uricase-a-multimeric-enzyme
#10
Khadijeh Alishah, Sedigheh Asad, Khosro Khajeh, Neda Akbari
Uric acid, a side product of nucleotide metabolism, should be cleared from blood stream since its accumulation can cause cardiovascular diseases and gout. Uricase (urate oxidase) converts uric acid to 5-hydroxyisourate, but it is absent in human and other higher apes. Yet, the recombinant form of uricase, Rasburicase, is now commercially available to cure tumor lysis syndrome by lowering serum uric acid level. Developing new methods to efficiently purify pharmaceutical proteins like uricase has attracted researchers' attention...
November 2016: Enzyme and Microbial Technology
https://www.readbyqxmd.com/read/27673324/preventing-and-managing-tumor-lysis-syndrome
#11
Roberta Kaplow, Karen Iyere
No abstract text is available yet for this article.
September 26, 2016: Nursing
https://www.readbyqxmd.com/read/27669655/robust-oncolytic-virotherapy-induces-tumor-lysis-syndrome-and-associated-toxicities-in-the-mpc-11-plasmacytoma-model
#12
Lianwen Zhang, Michael B Steele, Nathan Jenks, Jacquelyn Grell, Marshall Behrens, Rebecca Nace, Shruthi Naik, Mark J Federspiel, Stephen J Russell, Kah-Whye Peng
Tumor-selective oncolytic vesicular stomatitis viruses (VSVs) are being evaluated in clinical trials. Here, we report that the MPC-11 murine plasmacytoma model is so extraordinarily susceptible to oncolytic VSVs that a low dose of virus leads to extensive intratumoral viral replication, sustained viremia, intravascular coagulation, and a rapidly fatal tumor lysis syndrome (TLS). Rapid softening, shrinkage and hemorrhagic necrosis of flank tumors was noted within 1-2 days after virus administration, leading to hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia, increase in plasma cell free DNA, lymphopenia, consumptive coagulopathy, increase in fibrinogen degradation products, decreased liver function tests, dehydration, weight loss, and euthanasia or death after 5-8 days...
November 1, 2016: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/27659746/-analysis-of-the-2015%C3%A2-british-guidelines-on-the-prevention-and-management-of-tumor-lysis-syndrome
#13
A Dupré, C Mousseaux, A Bouguerba, S Ayed, J Barchazs, M Boukari, D Goldgran-Toledano, C Bornstain, F Vincent
Whether it appears spontaneously or is induced by therapy, the tumor lysis syndrome is responsible for a massive release of ions and puric bases degradation of products in the circulation exceeding the renal excretion capacity. Some, such as uric acid, xanthine, and calcium phosphate, can precipitate in the renal tubules or parenchyma. It must be known to any practitioner supporting patients with hematologic malignancies, mainly high-grade but also some solid tumors. The 2015 publication of the British recommendations pertaining to patients suffering from hematological diseases should be broadcast...
September 19, 2016: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/27641217/the-efficacy-of-febuxostat-10-mg-for-the-prevention-of-hyperuricemia-associated-with-tumor-lysis-syndrome-tls-in-japanese-patients-with-non-hodgkin-s-lymphoma%C3%A2
#14
Takeo Yasu, Shunsuke Kobayashi, Mai Horii, Yosuke Kurokawa
Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency. The control of serum uric acid level (UA) is important for prevention of TLS. Febuxostat has demonstrated its superiority over allopurinol in decreasing UA level. We retrospectively evaluated the efficacy of febuxostat 10 mg in prevention of hyperuricemia associated with TLS (HU-TLS) in 12 patients with non-Hodgkin's lymphoma (NHL). Mean UA levels were found to significantly decrease (p = 0.003). HU-TLS was prevented in all patients. Thus, febuxostat 10 mg is effective in prevention of HU-TLS...
December 2016: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27601914/clinical-use-of-blinatumomab-for-b-cell-acute-lymphoblastic-leukemia-in-adults
#15
REVIEW
Kum Ja Lee, Vivian Chow, Ashley Weissman, Sunil Tulpule, Ibrahim Aldoss, Mojtaba Akhtari
Adults with relapsed or refractory B-cell acute lymphoblastic leukemia have a dismal prognosis with a short median overall survival that can be measured in months. Because most patients will have chemotherapy-resistant disease, allogeneic hematopoietic stem cell transplantation remains the only potentially curative treatment. Despite advances in current management, patients continue to have poor outcomes and lack of durable responses. Thus, new therapies with alternative modes of actions are currently being investigated...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27563802/rasburicase-for-tumor-lysis-syndrome
#16
Swati Vishwanathan, Aravindhan Arumugarajah, Luis M Ortega, Alex Bousamra
No abstract text is available yet for this article.
August 18, 2016: American Journal of Therapeutics
https://www.readbyqxmd.com/read/27548821/serum-uric-acid-exhibits-inverse-relationship-with-estimated-glomerular-filtration-rate
#17
Abhilash Koratala, Girish Singhania, Kawther F Alquadan, Michiko Shimada, Richard J Johnson, A Ahsan Ejaz
BACKGROUND: In this study, we investigated the relationship between serum uric acid (SUA) and renal function in a unique patient cohort wherein SUA levels fluctuate during the course of standard care. METHODS: Correlation coefficients between SUA and serum creatinine (SCr) and kinetic estimated GFR (KeGFR) were retrospectively investigated in acute myeloid leukemia (AML) patients, and statistically significant and clinically relevant determinants were studied in multiple regression models...
August 23, 2016: Nephron
https://www.readbyqxmd.com/read/27521320/blinatumomab-bridging-the-gap-in-adult-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia
#18
REVIEW
Stephanie A Folan, Amber Rexwinkle, Jane Autry, Jeffrey C Bryan
Adult patients with acute lymphoblastic leukemia who relapse after frontline therapy have extremely poor outcomes despite advances in chemotherapy and hematopoietic stem cell transplantation. Blinatumomab is a first-in-class bispecific T-cell engager that links T cells to tumor cells leading to T-cell activation and tumor cell lysis. In December 2014, the Food and Drug Administration approved blinatumomab for treatment of relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia...
August 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27458036/xanthine-oxidoreductase-in-drug-metabolism-beyond-a-role-as-a-detoxifying-enzyme
#19
Maria Giulia Battelli, Letizia Polito, Massimo Bortolotti, Andrea Bolognesi
The enzyme xanthine oxidoreductase (XOR) catalyzes the last two steps of purine catabolism in the highest uricotelic primates. XOR is an enzyme with dehydrogenase activity that, in mammals, may be converted into oxidase activity under a variety of pathophysiologic conditions. XOR activity is highly regulated at the transcriptional and post-translational levels and may generate reactive oxygen and nitrogen species, which trigger different consequences, ranging from cytotoxicity to inflammation. The low specificity for substrates allows XOR to metabolize a number of endogenous metabolites and a variety of exogenous compounds, including drugs...
July 24, 2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27443101/-tumor-lysis-syndrome-in-a-pregnancy-complicated-with-acute-lymphoblastic-leukemia
#20
M P Álvarez-Goris, R Sánchez-Zamora, A A Torres-Aguilar, J C Briones Garduño
Acute leukemia is rare during pregnancy, affects about 1 in 75,000 pregnancies, of all leukemias diagnosed only 28% are acute lymphoblastic leukemia, this is a risk factor to develop spontaneous tumor lysis syndrome, it's a oncologic complication potentially deadly if the prophylactic treatment its avoided. Cases of acute lymphoblastic leukemia associated with pregnancy has been poorly documented in the literature the association of these two entities to pregnancy is the first report published worldwide, so the information is limited...
April 2016: Ginecología y Obstetricia de México
keyword
keyword
104429
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"